HPGC(SH:600664)2022-04-27 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥3,333,837,987.01, representing an increase of 11.88% compared to the same period last year [6] - The net profit attributable to shareholders of the listed company was ¥100,446,359.10, reflecting a growth of 21.21% year-on-year [6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥96,805,205.77, which is an increase of 88.58% compared to the previous year [6] - The basic earnings per share for the period was ¥0.04, up by 33.33% year-on-year [6] - Operating profit for Q1 2022 was CNY 160,484,032.82, up 20.6% from CNY 133,031,105.84 in Q1 2021 [31] - The total cost of operations for Q1 2022 was CNY 3,175,613,101.54, an increase of 10.4% from CNY 2,878,452,857.75 in Q1 2021 [28] - The total comprehensive income attributable to the parent company's owners for Q1 2022 was ¥100,715,949.51, compared to ¥82,744,240.91 in Q1 2021, representing an increase of approximately 21.5% [33] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,764,203,877.95, a decrease of 0.61% from the end of the previous year [8] - Total liabilities decreased to CNY 8,233,515,215.76 from CNY 8,421,954,031.68, a reduction of approximately 2.2% [28] - Total equity increased to CNY 4,530,688,662.19 from CNY 4,420,484,733.60, reflecting a growth of about 2.5% [28] - The company's total assets amounted to CNY 12,764,203,877.95, a slight decrease from CNY 12,842,438,765.28 [28] Cash Flow - The net cash flow from operating activities was ¥154,882,854.26, with a year-on-year comparison deemed not applicable [6] - Cash inflow from operating activities totaled ¥3,277,424,882.21 in Q1 2022, compared to ¥3,050,042,798.87 in Q1 2021, reflecting an increase of about 7.4% [33] - The net cash flow from operating activities for Q1 2022 was ¥154,882,854.26, a significant improvement from a net outflow of ¥173,741,428.63 in Q1 2021 [33] - Cash inflow from investment activities was ¥43,844,524.34 in Q1 2022, compared to ¥1,585,891.74 in Q1 2021, showing a substantial increase [34] - The net cash flow from investment activities for Q1 2022 was ¥11,988,054.23, recovering from a net outflow of ¥13,774,017.34 in Q1 2021 [34] - Cash inflow from financing activities in Q1 2022 was ¥583,415,780.00, down from ¥810,974,027.78 in Q1 2021, indicating a decrease of approximately 28.0% [34] - The net cash flow from financing activities for Q1 2022 was -¥5,098,076.67, compared to a positive net flow of ¥65,951,861.77 in Q1 2021 [34] - The ending balance of cash and cash equivalents as of Q1 2022 was ¥1,753,711,206.00, up from ¥775,151,835.18 at the end of Q1 2021, representing an increase of approximately 126.5% [34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 112,222, with the largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holding 1,173,237,023 shares, accounting for 46.56% [16] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., has pledged 926,857,248 shares [16] - There are no known related party transactions among the top shareholders [18] Research and Development - Research and development expenses for Q1 2022 were CNY 24,582,703.64, an increase of 9.7% compared to CNY 22,420,110.21 in Q1 2021 [29] Inventory and Receivables - The company experienced a decrease in other receivables by 44.04%, primarily due to repayments received [12] - Accounts receivable reached ¥4,199,524,541.69, up from ¥3,954,581,442.97 year-over-year, indicating a growth of approximately 6.2% [19] - Inventory decreased to ¥1,753,680,748.74 from ¥2,063,793,602.49, reflecting a reduction of about 15% [23] Other Information - The company has not disclosed any significant new product developments or market expansion strategies in the current report [18] - The company reported a decrease in other comprehensive income, with a net amount of CNY 269,590.41 compared to a loss of CNY 125,541.80 in Q1 2021 [31] - The company maintained a stable level of long-term borrowings at CNY 34,306,712.35, showing a minor increase from CNY 34,086,428.35 [28] - The company reported a significant decrease in cash outflow for employee payments, which was ¥394,603,625.37 in Q1 2022, down from ¥499,184,526.40 in Q1 2021, a reduction of about 20.9% [33]